| Stock Warrants |
As of March 31, 2022 and December 31, 2021, the Company had warrants to purchase the underlying common stock outstanding as shown in the table below.
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
| 2020 Warrants |
|
|
8,819,904 |
|
|
|
8,819,904 |
|
| 2017 Warrants |
|
|
1,599,645 |
|
|
|
1,599,645 |
|
| Pfizer Warrant |
|
|
505,617 |
|
|
|
505,617 |
|
| Other warrants (1) |
|
|
— |
|
|
|
1,428 |
|
| |
|
|
|
|
|
|
|
|
| Warrants to purchase common stock |
|
|
10,925,166 |
|
|
|
10,926,594 |
|
| |
|
|
|
|
|
|
|
|
| Weighted-average exercise price per share |
|
$ |
6.45 |
|
|
$ |
6.47 |
|
| |
|
|
|
|
|
|
|
|
| (1) |
Other warrants are comprised of warrants issued prior to the Company’s initial public offering (“IPO”), generally in exchange for services rendered to the Company. | The following table summarizes information regarding the Company’s warrants outstanding at March 31, 2022:
|
|
|
|
|
|
|
| |
|
Shares
Underlying
Outstanding
Warrants |
|
|
|
| $4.90 |
|
|
9,325,521 |
|
|
May 27, 2023 |
| $15.50 |
|
|
1,599,645 |
|
|
July 25, 2022 |
| |
|
|
|
|
|
|
| |
|
|
10,925,166 |
|
|
|
| |
|
|
|
|
|
|
|